Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome.

ABSTRACT:

Background

Bifidobacterium longum 35624 has shown efficacy in improving irritable bowel syndrome (IBS) symptoms compared with placebo in double-blind randomized studies. However, few data are available from real-life clinical practice or from studies that used Rome IV criteria to diagnose IBS.

Aim

To assess the effect of B. longum 35624 on IBS severity and quality of life in a real-life setting.

Methods

From November 2018 to January 2020, 278 patients with IBS (according to Rome IV criteria) were enrolled in a prospective, open-label, multicenter observational study by private practice gastroenterologists to received one capsule of B. longum 35624 (10⁹ colony-forming units) per day for 30 d. Participation in the study was indepen

SUBMITTER: Sabate JM 

PROVIDER: S-EPMC8891724 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature